Literature DB >> 25082161

Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation.

Sanjeet S Dadwal1, Bernard Tegtmeier, Xueli Liu, Paul Frankel, James Ito, Stephen J Forman, Vinod Pullarkat.   

Abstract

Invasive mold infections (IMI) are life-threatening complications of allogeneic hematopoietic stem cell transplantation (HSCT) and are mostly caused by Aspergillus species and Mucorales. We examined whether elevated serum ferritin prior to HSCT was associated with increased risk of IMI after allogeneic HSCT. Elevated serum ferritin was defined as values ≥ 1000 ng/mL. Pretransplant ferritin levels were available for 477 transplants. Nine developed IMI at day 30 and 21 had IMI at day 100 for a cumulative incidence of 1.9% and 4.4%, respectively. Among the high ferritin group, eight of 220 transplant cases (3.6%) developed an IMI within 30 d after HSCT compared with one of 257 (0.4%) in the low ferritin group (P = 0.01). Fourteen of 220 (6.4%) and seven of 257 transplant cases (2.7%) in the high and low ferritin groups, respectively, had developed an IMI by day 100 after HSCT (P = 0.07). Nine of 53 (17%) patients with grades III and IV acute GVHD and iron overload experienced IMI, when compared to three of 37 (8.1%) with high-grade aGVHD, but no iron overload. Among patients without aGVHD, those with elevated ferritin had a 2.7% incidence of IMI compared with 0.9% for patients without elevated ferritin. There was a marginally significant difference in cumulative incidence function between high and low ferritin groups for IMI (P = 0.06). However, elevated serum ferritin (≥ 1000 ng/mL) was not a significant risk factor for IMI in a multivariate competing risk regression model after adjusting for aGVHD.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allogeneic stem cell transplant; ferritin; infection; invasive mold; iron overload

Mesh:

Substances:

Year:  2014        PMID: 25082161     DOI: 10.1111/ejh.12421

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

Review 1.  Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies.

Authors:  F Lebrun; J Klastersky; D Levacq; Y Wissam; M Paesmans
Journal:  Support Care Cancer       Date:  2017-04-07       Impact factor: 3.603

Review 2.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

3.  American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.

Authors:  Sanjeet S Dadwal; Tobias M Hohl; Cynthia E Fisher; Michael Boeckh; Genofeva Papanicolaou; Paul A Carpenter; Brian T Fisher; Monica A Slavin; D P Kontoyiannis
Journal:  Transplant Cell Ther       Date:  2021-03

Review 4.  Iron overload in the HCT patient: a review.

Authors:  Pavan Tenneti; Aleksander Chojecki; Mary Ann Knovich
Journal:  Bone Marrow Transplant       Date:  2021-03-29       Impact factor: 5.174

5.  Association of Serum Ferritin Levels Before Start of Conditioning With Mortality After alloSCT - A Prospective, Non-interventional Study of the EBMT Transplant Complications Working Party.

Authors:  Olaf Penack; Christophe Peczynski; Steffie van der Werf; Jürgen Finke; Arnold Ganser; Helene Schoemans; Jiri Pavlu; Riitta Niittyvuopio; Wilfried Schroyens; Leylagül Kaynar; Igor W Blau; Walter J F M van der Velden; Jorge Sierra; Agostino Cortelezzi; Gerald Wulf; Pascal Turlure; Montserrat Rovira; Zubeydenur Ozkurt; Maria J Pascual-Cascon; Maria C Moreira; Johannes Clausen; Hildegard Greinix; Rafael F Duarte; Grzegorz W Basak
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

6.  Risk factors for Coronavirus disease-associated mucormycosis.

Authors:  Umang Arora; Megha Priyadarshi; Varidh Katiyar; Manish Soneja; Prerna Garg; Ishan Gupta; Vishwesh Bharadiya; Parul Berry; Tamoghna Ghosh; Lajjaben Patel; Radhika Sarda; Shreya Garg; Shubham Agarwal; Veronica Arora; Aishwarya Ramprasad; Amit Kumar; Rohit Kumar Garg; Parul Kodan; Neeraj Nischal; Gagandeep Singh; Pankaj Jorwal; Arvind Kumar; Upendra Baitha; Ved Prakash Meena; Animesh Ray; Prayas Sethi; Immaculata Xess; Naval Vikram; Sanjeev Sinha; Ashutosh Biswas; Alok Thakar; Sushma Bhatnagar; Anjan Trikha; Naveet Wig
Journal:  J Infect       Date:  2021-12-30       Impact factor: 6.072

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.